Citations

Clear

74 citation(s) found for "Nguyen, Phuong".

The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome per 2017 WHO guideline compared to de novo MDS.
Alkharabsheh, Omar , Al‐Kali, Aref , Saadeh, Salwa , He, Rong , Viswanatha, David S., Reichard, Kaaren K. , Gangat, Naseema , Patnaik, Mrinal M. , Litzow, Mark R. , Nguyen, Phuong L., Greipp, Patricia T. , Shah, Meera , Hogan, William J. , Alkhateeb, Hassan B.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e19026-e19026

10.1200/jco.2018.36.15_suppl.e19026 Get It

The impact of clonal size on the revised international prognostic scoring system (R-IPSS) in myelodysplastic syndromes (MDS) with a single cytogenetic abnormality.
Alkharabsheh, Omar , Saadeh, Salwa , Patnaik, Mrinal M. , Gangat, Naseema , Begna, Kebede H. , He, Rong , Nguyen, Phuong L., Litzow, Mark R. , Al‐Kali, Aref , Alkhateeb, Hassan B. , Hogan, William J. , Greipp, Patricia T.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 7068-7068

10.1200/jco.2018.36.15_suppl.7068 Get It

The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS
Alkharabsheh, Omar , Al‐Kali, Aref , Saadeh, Salwa , He, Rong , Viswanatha, David S., Greipp, Patricia T. , Reichard, Kaaren K. , Gangat, Naseema , Patnaik, Mrinal M. , Litzow, Mark R. , Nguyen, Phuong L., Viswanatha, David, Greipp, Patricia, Gangat, Naseema , Patnaik, Mrinal , Hogan, William, Litzow, Mark R. , Greipp, Patricia T , Shah, Meera , Hogan, William J. , Alkhateeb, Hassan B.

Mayo Clinic

American Journal of Hematology | August 7, 2018 | Volume: 93 | Issue: 11 | Pages: No page available

10.1002/ajh.25239 | PMID 30074268 Get It

Anti‐viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus‐related hepatocellular carcinoma: real‐world east and west experience
Chen, Vincent , Yeh, Ming-Lun, Le, An K. , Jun, Mi Jung, Saeed, Waqar Khalid , Yang, Ju Dong , Huang, Chung‐Feng , Lee, H. Y., Tsai, Pei‐Chien , Giama, Nasra H., Kim, N. G., Nguyen, Phuong , Dang, Hansen , Ali, Hamdi A. , Zhang, N., Chuang, Wan‐Long , Roberts, Lewis R. , Yu, Ming‐Lung , Nguyen, Mindie H. , Chen, V L , Huang, C-F , Jun, D W , Yu, M-L , Nguyen, Mindie H , Roberts, Lewis R , Yeh, Ming-Lun , Yang, Ju Dong , Lee, M.‐H., Huang, Jee‐Fu , Dai, Chia-Yen , Lim, Young‐Suk

Mayo Clinic

Alimentary Pharmacology & Therapeutics | May 24, 2018 | Volume: 48 | Issue: 1 | Pages: 44-54

10.1111/apt.14801 | PMID 29797518 Get It

SummaryBackgroundHepatitis B virus (HBV) is the leading cause of hepatocellular carcinoma (HCC) worldwide. It remains incompletely understood in the real world how anti‐viral therapy affects survival after HCC diagnosis.MethodsThis was an international multicentre cohort study of 2518 HBV‐related HCC cases diagnosed between 2000 and 2015. Cox proportional hazards models were utilised to estimate hazard ratios (HR) with 95% (CI) for anti‐viral therapy and cirrhosis on patients' risk of death.ResultsApproximately, 48% of patients received anti‐viral therapy at any time, but only 17% were on therapy at HCC diagnosis (38% at US centres, 11% at Asian centres). Anti‐viral therapy would have been indicated for >60% of the patients not on anti‐viral therapy based on American criteria. Patients with cirrhosis had lower 5‐year survival (34% vs 46%; P < 0.001) while patients receiving anti‐viral therapy had increased 5‐year survival compared to untreated patients (42% vs 25% with cirrhosis and 58% vs 36% without cirrhosis; P < 0.001 for both). Similar findings were seen for other patient subgroups by cancer stages and cancer treatment types. Anti‐viral therapy was associated with a decrease in risk of death, whether started before or after HCC diagnosis (adjusted HR 0.62 and 0.79, respectively; P < 0.001).ConclusionsAnti‐viral therapy improved overall survival in patients with HBV‐related HCC across cancer stages and treatment types but was underutilised at both US and Asia centres. Expanded use of anti‐viral therapy in HBV‐related HCC and better linkage‐to‐care for HBV patients are needed.
On Appetite and Its Loss
Jatoi, Aminah , Kumar, Shaji , Sloan, Jeff A. , Nguyen, Phuong

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 18 | Issue: 15 | Pages: 2930-2932

10.1200/jco.2000.18.15.2930 | PMID 10920143 Get It

Chemical exposures and risk of acute myeloid leukemia and myelodysplastic syndromes in a population‐based study
Poynter, Jenny N. , Richardson, Michaela , Roesler, Michelle A. , Blair, Cindy K. , Hirsch, Betsy , Cioc, Adina, Warlick, Erica D. , Nguyen, Phuong , Cerhan, James R.

Mayo Clinic

International Journal of Cancer | September 7, 2016 | Volume: 140 | Issue: 1 | Pages: 23-33

10.1002/ijc.30420 | PMID 27603749 Get It

Benzene exposure is one of the few well‐established risk factors for myeloid malignancy. Exposure to other chemicals has been inconsistently associated with hematologic malignancies. We evaluated occupational and residential chemical exposures as risk factors for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) using population‐based data. AML and MDS cases were identified by the Minnesota Cancer Surveillance System. Controls were identified through the Minnesota driver's license/identification card list. Chemical exposures were measured by self‐report. Unconditional logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CI). We included 265 MDS cases, 420 AML cases and 1388 controls. We observed significant associations between both MDS and AML and benzene (OR = 1.77, 95% CI 1.19, 2.63 and OR = 2.10, 95% CI 1.35, 3.28, respectively) and vinyl chlorides (OR = 2.05, 95% CI 1.15, 3.63 and OR = 2.81, 95% CI 1.14, 6.92). Exposure to soot, creosote, inks, dyes and tanning solutions and coal dust were associated with AML (range ORs = 2.68–4.03), while no association was seen between these exposures and MDS (range ORs = 0.57–1.68). Pesticides and agricultural chemicals were not significantly associated with AML or MDS. Similar results were observed in analyses stratified by sex. In addition to providing risk estimates for benzene from a population‐based sample, we also identified a number of other occupational and residential chemicals that were significantly associated with AML; however, all exposures were reported by only a small percentage of cases (≤10%). While chemical exposures play a clear role in the etiology of myeloid malignancy, these exposures do not account for the majority of cases.
Abstract 3427: Chemical exposures and risk of acute myeloid leukemia and myelodysplastic syndromes in a population-based study
Richardson, Michaela , Roesler, Michelle A. , Hirsch, Betsy , Cioc, Adina, Warlick, Erica D. , Poynter, Jenny N. , Blair, Cindy K. , Nguyen, Phuong , Cerhan, James R.

Mayo Clinic

Cancer Research | July 26, 2016 | Volume: 76 | Issue: 14_Supplement | Pages: 3427-3427

10.1158/1538-7445.am2016-3427 Get It

Abstract Background Myelodysplastic syndromes (MDS) are a group of clonal hematologic disorders that result in ineffective hematopoiesis. Individuals with MDS have a high risk of progressing to leukemia, with approximately 30% expected to develop acute myeloid leukemia (AML). Benzene exposure is one of the few well-established risk factors for AML, and recent studies suggest it is also a risk factor for MDS. Exposure to other occupational and residential chemicals has been inconsistently associated with hematologic malignancies. In this analysis, we evaluated occupational and residential chemical exposures as risk factors for AML and MDS using population-based data. Methods AML and MDS cases were identified by rapid case ascertainment through the Minnesota Cancer Surveillance System (MCSS). Centralized pathology and cytogenetics reviews were conducted to confirm diagnosis and classify by subtypes. Controls were identified through the Minnesota State driver's license/identification card list. Chemical exposures were measured by self-report and included occupational and residential exposure to a variety of chemicals. Unconditional logistic regression with adjustment for age, sex, previous cancer treatment, income, and farm or rural residence was used to calculate crude and adjusted odds ratios (ORs) and 95% confidence intervals (CI). Smoking, obesity and physical activity were considered as potential confounders but did not change effect estimates by 10% or more. Results We included 265 MDS cases, 420 AML cases, and 1388 controls in this analysis. As expected, we observed significant associations between benzene and both MDS and AML (OR = 1.77, 95% CI 1.17, 2.67 and OR = 2.03, 95% CI 1.45, 2.83, respectively). Exposure to vinyl chlorides was associated with MDS (OR = 2.25, 95% CI 1.32, 3.81) but not with AML (OR = 1.36, 95% CI 0.83, 2.21). Exposure to fertilizers (OR = 1.70, 95% CI 1.11, 2.59), soot (OR = 2.64, 95% CI 1.59, 4.39), creosote (OR = 1.95, 95% CI 1.08, 3.51), inks, dyes and tanning solutions (OR = 1.63, 95% 1.02, 2.60), and coal dust (2.64, 95% CI 1.30, 5.39) were associated with AML, while no association was seen between any of these exposures and MDS (range ORs = 0.78-1.25). No significant associations were observed for occupational pesticide exposures in either group. Discussion These data confirm the importance of benzene as a risk factor for myeloid malignancy and provide risk estimates in a population-based sample. A number of other significant associations with occupational and residential chemicals were observed for AML; however, all exposures were reported by only a small percentage of cases (≤10%). While chemical exposures play a clear role in the etiology of myeloid malignancy, these exposures do not account for the majority of cases. Citation Format: Jenny N. Poynter, Michaela Richardson, Michelle Roesler, Cindy K. Blair, Betsy Hirsch, Phuong Nguyen, Adina Cioc, James R. Cerhan, Erica Warlick. Chemical exposures and risk of acute myeloid leukemia and myelodysplastic syndromes in a population-based study. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3427.
Association between mitochondrial DNA haplogroup and myelodysplastic syndromes
Poynter, Jenny N. , Richardson, Michaela , Langer, Erica , Hooten, Anthony J. , Roesler, Michelle A. , Hirsch, Betsy , Cioc, Adina, Warlick, Erica D. , Ross, Julie A. , Nguyen, Phuong L., Nguyen, Phuong

Mayo Clinic

Genes, Chromosomes and Cancer | April 28, 2016 | Volume: 55 | Issue: 9 | Pages: 688-693

10.1002/gcc.22370 | PMID 27121678 Get It

Polymorphisms in mitochondrial DNA (mtDNA) are used to group individuals into haplogroups reflecting human global migration and are associated with multiple diseases, including cancer. Here, we evaluate the association between mtDNA haplogroup and risk of myelodysplastic syndromes (MDS). Cases were identified by the Minnesota Cancer Surveillance System. Controls were identified through the Minnesota State driver's license/identification card list. Because haplogroup frequencies vary by race and ethnicity, we restricted analyses to non‐Hispanic whites. We genotyped 15 mtSNPs that capture common European mitochondrial haplogroup variation. We used SAS v.9.3 (SAS Institute, Cary, NC) to calculate odds ratios (OR) and 95% confidence intervals (CI) overall and stratified by MDS subtype and IPSS‐R risk category. We were able to classify 215 cases with confirmed MDS and 522 controls into one of the 11 common European haplogroups. Due to small sample sizes in some subgroups, we combined mt haplogroups into larger bins based on the haplogroup evolutionary tree, including HV (H + V), JT (J + T), IWX (I + W + X), UK (U + K), and Z for comparisons of cases and controls. Using haplogroup HV as the reference group, we found a statistically significant association between haplogroup JT and MDS (OR = 0.58, 95% CI 0.36, 0.92, P = 0.02). No statistically significant heterogeneity was observed in subgroup analyses. In this population‐based study of MDS, we observed an association between mtDNA haplogroup JT and risk of MDS. While previously published studies provide biological plausibility for the observed association, further studies of the relationship between mtDNA variation and MDS are warranted in larger sample sizes. © 2016 Wiley Periodicals, Inc.
Loss of Blast Heterogeneity in Myelodysplastic Syndrome and Other Chronic Myeloid Neoplasms
Jevremović, Dragan , Timm, Michael, Reichard, Kaaren K. , Morice, William G. , Hanson, Curtis A. , Viswanatha, David S., Howard, Matthew T., Nguyen, Phuong L., Timm, Michael M, Morice, William George , Jevremovic, Dragan

Mayo Clinic

American Journal of Clinical Pathology | August 14, 2014 | Volume: 142 | Issue: 3 | Pages: 292-298

10.1309/ajcp73qsllydegxk | PMID 25125617 Get It

Abstract Objectives: Flow cytometry immunophenotyping has been suggested as an adjunctive technique in the evaluation of myeloid malignancies, especially in the myelodysplastic syndromes. However, its use has been limited due to complexity and cost restraints. The goal of this study is to attempt a simpler approach to flow cytometry immunophenotyping in myeloid neoplasms. Methods: We analyzed bone marrow specimens of 45 selected patients and an additional 99 consecutive random patients using a limited antibody panel. Results: Normal CD34-positive blasts show a characteristic pattern of CD13/HLA-DR expression, with three readily identifiable subpopulations. In contrast, myeloid neoplasms frequently show loss of this heterogeneity. Conclusions: Analysis of a limited antibody panel with a focus on CD13/HLA-DR expression provides relatively high specificity and sensitivity for the detection of myeloid neoplasms.